Therapeutic Development
Enable faster, more sensitive detection of treatment effects with objective cognitive endpoints that correlate with clinical meaningful change.
Concrete deliverables and measurements tailored to your environment
Multimodal cognitive endpoints that detect treatment-related cognitive change with high sensitivity and specificity.
Continuous measurement captures treatment signal earlier, potentially reducing enrollment needs and study duration.
Automated data collection and validation minimize missing data, protocol deviations, and site variability.
Audit trails, electronic consent, and comprehensive safety monitoring support FDA submissions and post-market surveillance.
Rigorous methodology and peer-reviewed research supporting this approach
Published data demonstrates cognitive endpoints detect meaningful treatment response in Alzheimer's, depression, and autism studies.
Measurement approach aligns with FDA guidance on digital health technologies, clinical outcome assessment, and remote monitoring.
Acceptance of multimodal cognitive assessment in clinical trials across Phase II, III, and post-market surveillance studies.
Reduced site burden and remote monitoring capability lower operational costs per subject enrolled.
Cognitive endpoints in Alzheimer's disease trials
Depression and treatment-resistant depression studies
Autism spectrum disorder intervention trials
Parkinson's disease and movement disorder assessments
ADHD medication efficacy and long-term monitoring
Neurodevelopmental disorder therapeutic trials